Tin tức & Cập nhật

The selective PPARδ* agonist seladelpar continues to demonstrate benefit in patients with primary biliary cholangitis (PBC) in the long-term pooled analysis from the ongoing open-label phase III ASSURE trial.

A suite of deep learning (DL) models to automate tuberculosis (TB) risk assessment from lung ultrasound (LUS) images fulfils the WHO criteria for a sputum-free TB triage test and outwits human experts in the TrUST study.